Desvenlafaxine Tablet, Extended Release
Product Images NDC 71205-586

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 71205-586). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-586-30 (Desvenlafaxine 100)

Label for Desvenlafaxine 100 mg extended release tablets, oral dosage form, in a package of 30 tablets. The label shows the ProficientRx logo and indicates the manufacturer as Alembic Pharmaceuticals Limited, India. The label includes NDC 71205-586-30 and states 'RX Only' along with storage instructions and medication guide information.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A forest plot chart showing geometric mean ratios with 90% confidence intervals for Cmax and AUC parameters of Desvenlafaxine in populations with varying renal and hepatic impairment, as well as by gender and age groups. The x-axis represents change relative to reference values with a baseline of 1.0.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A pharmacokinetic chart showing the geometric mean ratio with 90% confidence intervals for Cmax and AUC changes due to CYP3A4 inhibitor Ketoconazole, with relative changes plotted on a scale from 0.5 to 2.0 compared to reference.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A forest plot displaying geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) of Desvenlafaxine at various doses interacting with other drugs (Desipramine, Midazolam, Tamoxifen, Aripiprazole). The x-axis shows change relative to reference from 0.5 to 2.5. Multiple data points illustrate how Desvenlafaxine affects concentration and exposure of these drugs.*

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

A Kaplan-Meier curve illustrating the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine Extended-Release Tablets 50 mg and placebo. The graph shows lower relapse rates in the Desvenlafaxine group versus placebo throughout the approximately 200-day period.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

A Kaplan-Meier curve illustrating the estimated proportion of patients with relapse over time (days from randomization) for Desvenlafaxine Extended-Release Tablets versus placebo. The x-axis represents time to relapse in days, and the y-axis represents the estimated proportion of patients with relapse in percentage. Two lines compare relapse rates between the treatment and placebo groups.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

Chemical structure of desvenlafaxine succinate, showing molecular components including hydroxyl, methyl, and carboxyl groups along with a water molecule (H2O).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.